论文部分内容阅读
本研究测定了慢性丙型肝炎在IFN治疗前、治疗期间及治疗后血清Ⅲ型前胶原N-末端前肽(PⅢNP)、Ⅳ型胶原7S区(Ⅳ-7S)和透明质酸盐(HA)的水平,并研究了这些标记与IFN疗效间的关系, 研究对象为121例慢性丙型肝炎患者,男性89例,女性32例,年龄21～67岁。所有患者血清ALT水平超过正常上限1.5倍至少有6个月,血清HCV RNA阳性,HBV和自身免疫标记阴性。无1例接受过免疫调节或抗病毒治疗。IFN治疗前肝活检显示,慢性迁延性肝炎(CPH)29例,慢性活动性肝炎(CAH)2A 61例,CAH 2B 31例。IFN-α治疗为肌注每次6MU,开始2周每日1
This study measured the serum levels of serum type Ⅲ procollagen N-terminal propeptide (PⅢNP), type Ⅳ collagen 7S (IV-7S) and hyaluronate (HA) in patients with chronic hepatitis C before, during and after IFN treatment, The relationship between these markers and the efficacy of IFN was studied. The subjects were 121 patients with chronic hepatitis C, 89 males and 32 females, aged 21 to 67 years old. Serum ALT levels were 1.5 times more than the upper limit of normal for at least 6 months in all patients, with positive serum HCV RNA and negative HBV and autoimmune markers. None of the patients received immunomodulatory or antiviral treatment. Pre-IFN liver biopsy showed 29 cases of chronic persistent hepatitis (CPH), 61 cases of chronic active hepatitis (CAH) 2A and 31 cases of CAH 2B. IFN-α treatment for the intramuscular injection of 6MU each, start 2 weeks daily 1